A Phase 2a Multicenter Randomized Doubleblind Study Evaluating the Efficacy and Safety of Subcutaneously Administered combination therapy in Improving the Signs and Symptoms in Participants with Active Psoriatic Arthritis.

Go Back to All Clinical Trials

A Phase 2a Multicenter Randomized Doubleblind Study Evaluating the Efficacy and Safety of Subcutaneously Administered combination therapy in Improving the Signs and Symptoms in Participants with Active Psoriatic Arthritis.

Brief description of study

This is a Phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept (POC) clinical study designed to evaluate the efficacy and safety of combination therapy with guselkumab+golimumab (guselkumab 100 mg q4w + golimumab 50 mg q4w) versus guselkumab monotherapy (guselkumab 100 mg q4w + placebo) in adults with active PsA who have a previous history of IR to one anti-TNFa therapy either due to primary nonresponse or loss of efficacy.

Clinical Study Identifier: s21-00936

ClinicalTrials.gov Identifier: NCT05071664

Principal Investigator: Jose U Scher.

Other Investigators: Soumya M Reddy, Rebecca Haberman, Fardina Malik, Michael Toprover, Rebecca Barbara Blank.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies